Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Acquires $20,520.00 in Stock

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd bought 12,000 shares of Vigil Neuroscience stock in a transaction on Thursday, December 19th. The stock was purchased at an average price of $1.71 per share, with a total value of $20,520.00. Following the completion of the acquisition, the director now directly owns 12,000 shares of the company’s stock, valued at $20,520. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Vigil Neuroscience Trading Up 2.4 %

NASDAQ:VIGL opened at $1.70 on Friday. Vigil Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $6.06. The company has a market cap of $69.49 million, a PE ratio of -0.83 and a beta of 1.65. The company’s 50 day moving average is $3.02 and its two-hundred day moving average is $3.50.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VIGL. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a research report on Friday, November 8th. Wedbush lifted their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. William Blair started coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vigil Neuroscience has a consensus rating of “Buy” and an average target price of $19.75.

Institutional Investors Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC purchased a new position in Vigil Neuroscience in the 2nd quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vigil Neuroscience during the 2nd quarter valued at about $87,000. Renaissance Technologies LLC increased its holdings in shares of Vigil Neuroscience by 19.2% in the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares during the period. Walleye Capital LLC raised its stake in shares of Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Vigil Neuroscience during the third quarter worth about $442,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.